| 000 | 01245 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250512001407.0 | ||
| 264 | 0 | _c19861110 | |
| 008 | 198611s 0 0 eng d | ||
| 022 | _a0031-4005 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAndrews, A F | |
| 245 | 0 | 0 |
_aOne- to three-year outcome for 14 neonatal survivors of extracorporeal membrane oxygenation. _h[electronic resource] |
| 260 |
_bPediatrics _cOct 1986 |
||
| 300 |
_a692-8 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aCerebral Hemorrhage _xetiology |
| 650 | 0 | 4 |
_aDevelopmental Disabilities _xetiology |
| 650 | 0 | 4 | _aElectroencephalography |
| 650 | 0 | 4 | _aExtracorporeal Circulation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGrowth |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aIntelligence Tests |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOxygenators, Membrane _xadverse effects |
| 650 | 0 | 4 |
_aRespiratory Distress Syndrome, Newborn _xtherapy |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aTolazoline _xtherapeutic use |
| 700 | 1 | _aNixon, C A | |
| 700 | 1 | _aCilley, R E | |
| 700 | 1 | _aRoloff, D W | |
| 700 | 1 | _aBartlett, R H | |
| 773 | 0 |
_tPediatrics _gvol. 78 _gno. 4 _gp. 692-8 |
|
| 999 |
_c2435302 _d2435302 |
||